Combining Daily Migraine Prevention with Acute Treatment
Evidence-Based Support
- The 2023 VA/DoD Clinical Practice Guideline suggests atogepant for the prevention of episodic migraine (weak recommendation) 1, 2, 3
- The 2025 American College of Physicians guideline addresses atogepant as a treatment option for episodic migraine prevention, though it emphasizes cost considerations when selecting among preventive agents 4
- Atogepant is designed for continuous daily use to reduce migraine frequency and severity over time 1
- The 2023 VA/DoD guideline provides a strong recommendation for rizatriptan as an abortive treatment for acute migraine attacks 2, 3
Clinical Implementation
- Take atogepant daily as prescribed, regardless of whether migraine attacks occur 1
- Allow 2-3 months for full therapeutic effect to manifest before assessing efficacy 4
- Continue preventive therapy even when using acute medications, as they serve complementary roles 3
- Use rizatriptan 10 mg at the early onset of migraine headache for maximum effectiveness 5
- Rizatriptan can be taken as needed for individual migraine attacks while maintaining daily atogepant 2
Safety Considerations
- Limit rizatriptan use to no more than twice weekly to prevent medication overuse headache 5
- If you find yourself needing acute medication more frequently, reassess the preventive regimen rather than increasing abortive medication frequency 5
- Document migraine frequency and acute medication use to monitor for overuse patterns 5
Monitoring and Adjustment
- Reassess the effectiveness of both preventive and acute treatments after 2-4 weeks of combined therapy 5
- If atogepant provides inadequate prevention after 2-3 months at target dose, consider switching to alternative preventive agents with stronger evidence (CGRP monoclonal antibodies, candesartan, telmisartan, topiramate) 1, 3, 4
- Maintain a headache diary to track migraine frequency, severity, and medication response 4